Abstract：
BACKGROUND: The efficacy of liraglutide for treating type 2 diabetes mellitus and obesity is well established, but their role in the treatment of weight regain after bariatric surgery remains unclear.
METHODS: We searched PubMed, Embase, and Cochrane Library databases in January 2024. A random-effects model was employed to compute mean differences (MD) and events per 100 observations with 95% confidence intervals (CI) for continuous and binary endpoints. Statistical analysis was performed using R software.
RESULTS: A total of 16 studies were included and 881 individuals. Patients were mostly female (50%), aged 36 to 55 years, with a mean body mass index (BMI) of 39.4 kg/m2, and had BS surgery 5 years prior. Over a mean follow-up time ranging from 3 months to 4 years, it was observed a statistically significant reduction in BMI (MD - 8.56 kg/m2; 95% CI 3.34 to 13.79; p < 0.01) and a mean reduction in total weight (MD - 16.03 kg; 95% CI 0.03 to 32.02; p = 0.05) after liraglutide use. Additionally, 65% of patients undertaking liraglutide showed total body weight loss (BWL) above 5% (65.8 events per 100 observations; 95% CI 54.96 to 75.20; p < 0.01), while 26% lost more than 10% of total BWL (26.77 events per 100 observations; 95% CI 19.17 to 36.02; p < 0.01). A limitation is a variability between the studies.
CONCLUSIONS: Our findings support the use of liraglutide for weight management in patients who experience weight regain after BS. Liraglutide is well tolerated and promotes significant weight loss, providing clinicians with a therapeutic option for this clinical challenge.
METHODS: We searched PubMed, Embase, and Cochrane Library databases in January 2024. A random-effects model was employed to compute mean differences (MD) and events per 100 observations with 95% confidence intervals (CI) for continuous and binary endpoints. Statistical analysis was performed using R software.
RESULTS: A total of 16 studies were included and 881 individuals. Patients were mostly female (50%), aged 36 to 55 years, with a mean body mass index (BMI) of 39.4 kg/m2, and had BS surgery 5 years prior. Over a mean follow-up time ranging from 3 months to 4 years, it was observed a statistically significant reduction in BMI (MD - 8.56 kg/m2; 95% CI 3.34 to 13.79; p < 0.01) and a mean reduction in total weight (MD - 16.03 kg; 95% CI 0.03 to 32.02; p = 0.05) after liraglutide use. Additionally, 65% of patients undertaking liraglutide showed total body weight loss (BWL) above 5% (65.8 events per 100 observations; 95% CI 54.96 to 75.20; p < 0.01), while 26% lost more than 10% of total BWL (26.77 events per 100 observations; 95% CI 19.17 to 36.02; p < 0.01). A limitation is a variability between the studies.
CONCLUSIONS: Our findings support the use of liraglutide for weight management in patients who experience weight regain after BS. Liraglutide is well tolerated and promotes significant weight loss, providing clinicians with a therapeutic option for this clinical challenge.
摘要：
背景：利拉鲁肽治疗2型糖尿病和肥胖症的疗效已得到证实，但它们在减肥手术后体重恢复治疗中的作用仍不清楚。
方法：我们搜索了PubMed，Embase,以及2024年1月的Cochrane图书馆数据库。采用随机效应模型来计算平均差（MD）和每100个观测值的事件，对于连续和二元端点具有95％的置信区间（CI）。使用R软件进行统计学分析。
结果：共纳入16项研究和881名个体。患者大多为女性（50%），年龄36至55岁，平均体重指数（BMI）为39.4kg/m2，并且在5年前进行了BS手术。平均随访时间为3个月至4年，使用利拉鲁肽后,BMI显著降低(MD-8.56kg/m2;95%CI3.34~13.79;p<0.01),总重量平均降低(MD-16.03kg;95%CI0.03~32.02;p=0.05).此外,接受利拉鲁肽治疗的患者中，有65%的患者的总体体重减轻（BWL）超过5%（每100次观察有65.8次事件；95%CI54.96至75.20；p<0.01），而26%的患者失去了超过10%的总BWL(26.77个事件/100次观察;95%CI19.17至36.02;p<0.01)。限制是研究之间的可变性。
结论：我们的研究结果支持在BS术后体重恢复的患者中使用利拉鲁肽进行体重管理。利拉鲁肽耐受性良好，可促进明显的体重减轻，为临床医生提供应对这一临床挑战的治疗选择。
方法：我们搜索了PubMed，Embase,以及2024年1月的Cochrane图书馆数据库。采用随机效应模型来计算平均差（MD）和每100个观测值的事件，对于连续和二元端点具有95％的置信区间（CI）。使用R软件进行统计学分析。
结果：共纳入16项研究和881名个体。患者大多为女性（50%），年龄36至55岁，平均体重指数（BMI）为39.4kg/m2，并且在5年前进行了BS手术。平均随访时间为3个月至4年，使用利拉鲁肽后,BMI显著降低(MD-8.56kg/m2;95%CI3.34~13.79;p<0.01),总重量平均降低(MD-16.03kg;95%CI0.03~32.02;p=0.05).此外,接受利拉鲁肽治疗的患者中，有65%的患者的总体体重减轻（BWL）超过5%（每100次观察有65.8次事件；95%CI54.96至75.20；p<0.01），而26%的患者失去了超过10%的总BWL(26.77个事件/100次观察;95%CI19.17至36.02;p<0.01)。限制是研究之间的可变性。
结论：我们的研究结果支持在BS术后体重恢复的患者中使用利拉鲁肽进行体重管理。利拉鲁肽耐受性良好，可促进明显的体重减轻，为临床医生提供应对这一临床挑战的治疗选择。
